Frankfurt
06.12.24 | 08:01
0,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln | |||||
| 27.12.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.12.2024 | 1.312 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.12.2024ISIN NameCA33812R1091 FISSION... ► Artikel lesen | |
| 16.12.24 | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 223 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 06.12.24 | XFRA 4CX: AUSSETZUNG/SUSPENSION | 241 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen | |
| 12.11.24 | Nasdaq Stockholm AB: Cyxone AB receives observation status | 277 | GlobeNewswire | On November 8, 2024, Cyxone AB (the "Company") disclosed a press release with
information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can... ► Artikel lesen | |
| 08.11.24 | Nasdaq Stockholm AB: Lift of Suspension in Cyxone AB at FNSE | 297 | GlobeNewswire | Lifting of Suspension
At Trading Venue FNSE
Issuer: Cyxone AB, LEI: 54930034OH16ROAY4K87
--------------------------------------------------------------------------------
Instruments:... ► Artikel lesen | |
| 26.07.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.07.2024 | 411 | Xetra Newsboard | Das Instrument 1NN ES0105251005 NEINOR HOMES SA EO 8,21 EQUITY wird cum Kapitalmassnahme gehandelt am 26.07.2024 und ex Kapitalmassnahme am 29.07.2024 The instrument 1NN ES0105251005 NEINOR HOMES SA... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| VALNEVA | 2,420 | -0,49 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
| NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| BAVARIAN NORDIC | 22,640 | -0,70 % | Bavarian Nordic A/S: Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women | First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,680 | -8,22 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,250 | +1,81 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| ORAGENICS | 4,060 | +14,85 % | ORAGENICS INC - S-1, General form for registration of securities | ||
| LEXICON PHARMACEUTICALS | 0,734 | +3,67 % | H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock | ||
| OUTLOOK THERAPEUTICS | 1,435 | +2,72 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD | ISELIN, N.J., June 10, 2025(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,450 | -5,46 % | CSTONE PHARMA-B (02616): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | ||
| GENSCRIPT BIOTECH | 1,634 | +3,19 % | GenScript Biotech Corporation Reports FY 2024 Results | Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth.
PISCATAWAY, N.J., March 12, 2025 /PRNewswire/... ► Artikel lesen | |
| KRYSTAL BIOTECH | 120,00 | +1,18 % | Krystal Biotech, Inc.: Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa | Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,310 | +0,49 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
| Q32 BIO | 1,280 | -0,78 % | Q32 Bio Inc. - 8-K, Current Report | ||
| ALIGOS THERAPEUTICS | 6,250 | +0,81 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient... ► Artikel lesen |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.